<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02621242</url>
  </required_header>
  <id_info>
    <org_study_id>49167</org_study_id>
    <nct_id>NCT02621242</nct_id>
  </id_info>
  <brief_title>Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals</brief_title>
  <official_title>Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As explained in detail in a recently published hypothesis article (Hladik F. A new hypothesis
      on HIV cure. F1000Research, 4:77 (2015)), the investigators hypothesize that NRTI drugs may
      reduce the likelihood of HIV eradication by promoting the survival of cells with integrated
      provirus. In this study, the investigators will test whether daily oral use of two NTRI
      drugs, tenofovir and emtricitabine (Truvada Pill), induces changes in the upper and lower gut
      mucosa that are congruent with supporting this hypothesis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interleukin-10 (IL-10) and mitochondrially encoded ATP synthase 6 (MT-ATP6) mRNA copy numbers.</measure>
    <time_frame>2-3 months after initiating HIV Pre-exposure prophylaxis</time_frame>
    <description>Copy numbers per 1000 copies of the housekeeping gene hemoglobin B (HBB) (copies / 1000 HBB copies)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Global transcriptome analysis</measure>
    <time_frame>2-3 months after initiating HIV Pre-exposure prophylaxis</time_frame>
    <description>Global transcriptome analysis tests for expression changes of any possible gene across the entire human genome in response to Truvada PrEP. The main outcome of such an analysis is the number of genes significantly changing in expression between before and after treatment. We will report that Truvada PrEP up-regulates X number of genes and down-regulates Y number of genes.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects will undergo all procedures</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Upper endoscopy</intervention_name>
    <description>Upper endoscopy with biopsies</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Anoscopy</intervention_name>
    <description>Anoscopy with biopsies</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada</intervention_name>
    <description>Truvada (tenofovir/emtricitabine) daily as HIV pre-exposure prophylaxis. This medication will not be provided by the study.</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • HIV-negative

               -  Male gender at birth

               -  Age ≥18 years old

               -  Intent to initiate PrEP in the next 1-2 months.

               -  Willingness and ability to provide informed consent for study participation

               -  Willingness to undergo all required study procedures

        Exclusion Criteria:

          -  Creatinine clearance &lt; 60mL/min

          -  Platelet count below the normal reference

          -  Coagulation (PT/PTT) tests above the normal reference

          -  Any prior use of PrEP

          -  Use of PEP within 30 days prior to study entry

          -  Receipt of

               -  anti-coagulant medications (e.g. warfarin). Aspirin is allowable.

               -  Systemic corticosteroid medications

               -  Non-steroidal anti-inflammatory drug (NSAID) use &gt;2 days/week

          -  Signs or symptoms of acute HIV infection within 14 days of study entry

          -  No availability of another person who will drive participant home on days of entry and
             follow-up procedures.

          -  Plan to leave the Seattle area in the subsequent 2.5 months

          -  Any condition or substance use that, in the opinion of the study investigator, would
             interfere with study participation.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne Stekler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Joanne Stekler</investigator_full_name>
    <investigator_title>Associate Professor, Division of Allergy &amp; Infectious Diseases</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

